+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07549412

Randomized Phase 3 Study Comparing Precemtabart Tocentecan With or Without Bevacizumab Versus TrifluridineTipiracil Plus Bevacizumab for Previously Treated Metastatic Colorectal Cancer

Led by EMD Serono Research & Development Institute, Inc. · Updated on 2026-10-08

1020

Participants Needed

92

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating treatments for participants with metastatic colorectal cancer mCRC who have previously received irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab. The study aims to compare overall survival when using precemtabart tocentecan Precem-TcT alone, Precem-TcT combined with bevacizumab, and trifluridinetipiracil FTD-TPI plus bevacizumab. This Phase 3 trial addresses the unmet need for effective treatment options in this patient group. Participants will be randomly assigned to one of three groups Precem-TcT alone given intravenously every 3 weeks on Day 1 of each 21-day cycle Precem-TcT combined with bevacizumab administered intravenously every 3 weeks or every 2 weeks depending on the cycle or FTD-TPI tablets taken orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle along with bevacizumab. The study evaluates these treatments over cycles lasting up to an average of 19 months. During the study, participants will undergo various assessments including survival monitoring, disease progression checks, response evaluations using RECIST criteria, adverse event tracking, and quality of life questionnaires. Blood samples will be collected at specific times to measure drug concentrations and immune response markers. Researchers will assess physical functioning and health status repeatedly until treatment ends, with safety and treatment effects monitored throughout the trial period.

CONDITIONS

Brief Title

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Research Team

U

US Medical Information

C

Communication Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here